Lipid-modifying drugs
Mann, J.; Scott, R.
New Zealand Medical Journal 111(1071): 285-287
1998
ISSN/ISBN: 0028-8446 PMID: 9760951 Document Number: 494052
Document emailed within 1 workday
Related Documents
Sánchez, T.; Contreras-Yáñez, Iú.; Elías-López, D.; Aguilar Salinas, C.A.; Pascual-Ramos, V. 2014: Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs Clinical and Experimental Rheumatology 32(4): 509-515Mielens, Z.E.; Connolly, K.; Stecher, V.J. 1985: Effect of disease modifying antirheumatic drugs and nonsteroidal antiinflammatory drugs upon cellular and fibronectin responses in a pleurisy model Journal of Rheumatology 12(6): 1083-1087
Doncheva, N.I.; Nikolov, K.V.; Vassileva, D.P. 2006: Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia Folia Medica 48(3-4): 56-61
Efimova, S.S.; Schagina, L.V.; Ostroumova, O.S. 2017: Dipole-Modifying effect of Styrylpyridinium Dyes and Flavonoids on the Model Membranes of different Lipid Compositions Tsitologiia 59(3): 229-235
Harth, M. 1992: Mechanisms of action of disease modifying antirheumatic drugs Journal of Rheumatology. Suppl 32: 100-103
Takahashi, N.; Ishiguro, N. 2016: Mechanism of action of biological disease--modifying antirheumatic drugs Nihon Rinsho. Japanese Journal of Clinical Medicine 74(6): 882-886
Capell, H. 2002: Longterm maintenance therapy with disease modifying antirheumatic drugs Journal of Rheumatology. Supplement 66: 38-43
Sidorenko, T.V.; Boĭko, A.N.; Davydovskaia, M.F.; Zolotova, S.N.; Lash, N.I.; Popova, N.F.; Khachanova, N.V.; Shur, S.G.; Gusev, E.I. 2009: Adherence to long-term therapy with disease modifying drugs Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 109(7 Suppl 2: 107-113
Scott, I.C.; Kingsley, G.H.; Scott, D.L. 2013: Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis? Clinical and Experimental Rheumatology 31(4 Suppl 78: S4-S8
Martens, L.L.; Guibert, R. 1994: Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease Clinical Therapeutics 16(6): 1052-62; discussion 1036
Galindo-Rodriguez, G.; Aviña-Zubieta, J.A.; Russell, A.S.; Suarez-Almazor, M.E. 1999: Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study Journal of Rheumatology 26(11): 2337-2343
Pohjankoski, H.; Latva, K.; Kautiainen, H.; Säilä, H.; Klaukka, T.; Virta, L.; Puolakka, K.; Pohjolainen, T.; Savolainen, A. 2011: First-year purchases of disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland Clinical and Experimental Rheumatology 29(5): 878-881
Müller, P.; Dammann, H.G.; Langer, M.; Leucht, U.; Simon, B. 1989: Ranitidine ameliorates acemetacin and indomethacin-induced changes of the gastroduodenal mucosa, without modifying the pharmacokinetic behavior of both antirheumatic drugs Zeitschrift für Gastroenterologie 27(2): 83-86
Osiri, M.; Akkasilpa, S.; Deesomchok, U. 2000: Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study Journal of the Medical Association of Thailand 83(3): 217-224
Santanu, G.; Suhrita, P.; Mookerjee, S.; Tania, K.; Mita, S.; Pramit, G.; Sharmila, G.; Miraj, M.; Debdutta, M. 2011: Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease Indian Heart Journal 63(5): 434-437
Auer, J.; Berent, R.; Weber, T.; Porodko, M.; Mayr, H.; Maurer, E.; Eber, B. 2001: Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents Wiener Medizinische Wochenschrift 151(1-2): 13-17
Aletaha, D.; Smolen, J.S. 2002: Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study Journal of Rheumatology 29(8): 1631-1638
Gibofsky, A.; Cannon, G.W.; Harrison, D.J.; Joseph, G.J.; Bitman, B.; Chaudhari, S.; Collier, D.H. 2015: Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2) Clinical and Experimental Rheumatology 33(3): 297-301
Dougados, M. 2004: Outcome measures for clinical trials of disease modifying osteoarthritis drugs in patients with hip osteoarthritis Journal of Rheumatology. Suppl 70: 66-69
Le Loët, X.; Nordström, D.; Rodriguez, M.; Rubbert, A.; Sarzi-Puttini, P.; Wouters, J.M.G.W.; Woolley, J.Michael.; Wright, N.; Lawrence, C.; Appleton, B. 2008: Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial Journal of Rheumatology 35(8): 1538-1544